Navigation Links
InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
Date:2/3/2009

- CAPACITY 2 Meets Primary and Key Secondary Endpoints -

- CAPACITY 1 Misses Primary Endpoint, Provides Supportive Data -

- Company Preparing to Submit NDA and MAA -

BRISBANE, Calif., Feb. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF).

The primary endpoint of change in percent predicted Forced Vital Capacity (FVC) at Week 72 was met with statistical significance in CAPACITY 2 (p=0.001), along with the secondary endpoints of categorical change in FVC and progression-free survival (PFS). The primary endpoint was not met in CAPACITY 1 (p=0.501), but supportive evidence of a pirfenidone treatment effect was observed on a number of measures. Pirfenidone was safe and generally well tolerated in both CAPACITY studies. The company is preparing a New Drug Application (NDA) for submission to the FDA, to be followed by a Marketing Authorization Application (MAA) submission to the EMEA.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "We are very pleased by the overall efficacy and safety of pirfenidone in the treatment of IPF provided by the two CAPACITY studies. In CAPACITY 2, pirfenidone demonstrated a robust treatment effect on the primary endpoint and key secondary endpoints. Although the effect of pirfenidone did not achieve statistical significance on the primary endpoint in CAPACITY 1, the overall treatment effect of pirfenidone was in many respects similar in both studies. The totality of the data from these two studies suggests that pirfenidone has a positive treatment effect on patients with IPF. We believe that the efficacy data from both of the CAPACITY studies as well as Shionogi's Phase 3 stu
'/>"/>

SOURCE InterMune
Copyright©2009 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at J.P. Morgan Healthcare Conference
2. InterMune to Present at Deutsche Bank Biotech Boston Confab
3. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
4. InterMune to Release Third Quarter 2008 Financial Results on November 6
5. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
6. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
7. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
8. InterMune to Present at Canaccord Adams Conference
9. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
10. InterMune to Present at BMO Healthcare Conference
11. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... A recent study from researchers in ... find that those who took probiotics were able to run ... study showed that in extreme heat conditions, probiotics were able ... acne treatment explains what this new discovery means ... their skin condition. , While researchers tote the benefits ...
(Date:5/21/2013)... 2013 First patients dosed with ... bromide designed using Prosonix, particle engineering platform ... of inhaled Respiratory Medicines by Design , has ... will assess its effect on lung function and the ... moderate to severe chronic obstructive pulmonary disease (COPD). The ...
(Date:5/21/2013)... Custom Learning Designs, Inc.(CLD) unveils the ... Tin Can API combined with its own proprietary ... leading developer of training content and solutions for ... , Tin Can API is a cost-effective learning ... more accurately measure the Return on Education (ROE) ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Alpha ... distributor , will be exhibiting for the 13th ... of Medical Instrumentation (AAMI) 2013 Conference and Expo. ... support, distribute, and manufacture healthcare technologies. This year’s ... Long Beach, California. , The three-day event ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2
... 2011 UV Flu Technologies, Inc. ( ... to announce it has expanded its International Distribution by adding ... its relationship with the Company,s Distributor in India, Ormed Systems, ... as well as other parts of the world. The Company ...
... Avaxia Biologics, Inc. , a privately-held biotech ... the gastrointestinal tract, announced today that the company completed ... A angel-led financing. Cherrystone Angels of Providence, Rhode Island ... and other undisclosed individuals. Mr. Robert Manning, the co-Chairman ...
... SQNM ), a life sciences company providing innovative ... Lazard Capital Markets 8th Annual Healthcare Conference at the Pierre ... Harry F. Hixson, Jr, Ph.D., Chairman and CEO, and Ronald ... will present on Tuesday, November 15, 2011 beginning at 8:30 ...
Cached Biology Technology:UV Flu Technologies Expands Its International Footprint 2UV Flu Technologies Expands Its International Footprint 3Avaxia Biologics, Inc. Raises $2.2 Million in First Closing of Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease 2Sequenom Announces Participation at the Lazard Capital Markets 8th Annual Healthcare Conference 2
(Date:5/22/2013)... Researchers working to improve durability in fuel cell ... University, have discovered links between electrode degradation processes ... quantifying the effects of electrode degradation stressors in ... membrane lifetime. , The findings of the study, ... the latest in a long-term study at Burnaby-based ...
(Date:5/22/2013)... drastically reduces the time and effort needed to ... biotechnology, scientists are reporting. Published in the journal ... the way for more rapid development of designer ... activities. , Keith Shearwin and colleagues explain that ... material DNA into a bacterium,s genome is critical ...
(Date:5/22/2013)... on how climate change will affect interactions between species ... Journal of Animal Ecology . This knowledge, they say, ... of how species are likely to be impacted by ... recognition among biologists that climate change is affecting how ... going to have very important consequences for the stability ...
Breaking Biology News(10 mins):Tests lead to doubling of fuel cell life 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... Carolina State University have found a specific gene in corn that ... diseases. In a paper ... Sciences , NC State plant pathologists and crop scientists pinpoint ... to Southern leaf blight, gray leaf spot and Northern leaf blight, ...
... use of biotechnology increases and more companies move ... to begin full-scale commercialization of seed mixtures in ... will become even more difficult. "Seed mixtures ... of larval behavior and greater adoption of insecticidal ...
... has for the first time found that female-to-male transsexual ... traits. , The Medical Research Council (MRC) funded ... and Developmental Disorders , has important implications for the ... persists into adulthood, and for the ,extreme male brain, ...
Cached Biology News:Study shows corn gene provides resistance to multiple diseases 2Seed mixtures and insurance pest management: Future norm in the Corn Belt? 2Female-to-male transsexual people have more autistic traits 2
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Trop-2 Purified Anti-Human clone 162-46, Isotype Mouse IgG 1 , 100 µg Consult technical datasheet for details....
... BAC (100+kb), fosmid (40kb), and large plasmid ... any othe BAC vector. On command 20-50 ... easy recombinant DNA purification. Available with blue-white ... vectors for the highest insert stability. Kits ...
... Adapted to Sf-900 II ... isolated from Spodoptera frugiperda ... cells (1). The Sf21 ... serum-free suspension culture in ...
Biology Products: